Full-Time

WMS Product Analyst – IT Lead

Deadline 9/14/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Memphis, TN, USA

Hybrid

Three days in the office and two days remote.

Master's

Category
Product (1)
Required Skills
Middleware
Agile
Machine Learning
SAP Products
SCRUM
REST APIs
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Bachelor’s degree in information technology, Computer Science, Supply Chain, Engineering, Business, or related field required
  • Master’s Degree preferred
  • Minimum 8+ years of experience in Supply Chain Technology, Warehouse Management Systems, or Distribution Operations
  • Experience supporting Warehouse Management Systems such as SAP EWM, SAP WM, Blue Yonder/JDA, Körber/STEPLogic or Trace, Manhattan, MARC WMS or equivalent solutions
  • Strong knowledge of warehouse and logistics business processes
  • Experience leading product, business analysis, or technology delivery initiatives
  • Ability to translate business requirements into process flows, epics, user stories, and functional specifications
  • Experience supporting Agile and Scrum methodologies
  • Strong analytical, problem-solving, and solution design skills
  • Experience managing complex stakeholder relationships
  • Excellent written, verbal, and presentation communication skills
  • Ability to operate effectively in a fast-paced manufacturing and distribution environment
  • Required Skills: Business Process Development, Order to Cash (OTC), Process Flow, Warehouse Management
  • Desirable: Experience with SAP EWM implementations, migrations, or warehouse modernization programs
  • Desirable: Experience supporting automation, robotics, ASRS, conveyor, or material handling technologies
  • Desirable: Knowledge of SAP S/4HANA, SAP TM, SAP ERP, or related supply chain applications
  • Desirable: Experience with cloud technologies, integrations, middleware, or API-driven architecture
  • Desirable: Exposure to AI, machine learning, analytics, or digital supply chain initiatives
  • Desirable: Experience supporting FDA, GxP, SOX, or regulated environments
  • Desirable: Project Management certification and/or Agile certification preferred
  • Desirable: Strategic thinking and business acumen
  • Desirable: Technology leadership
  • Desirable: Product ownership mindset
  • Desirable: Execution excellence
  • Desirable: Customer focus
  • Desirable: Data-driven decision making
  • Desirable: Continuous improvement orientation
  • Desirable: Strong collaboration and influencing skills
  • Desirable: Commitment to Johnson & Johnson Credo values
  • Desirable: Travel up to 15–25% may be required
  • Desirable: Hybrid working (3 days in the office and 2 days remote)
  • Desirable: On-site presence at Memphis Logistics Center is expected
  • Desirable: This role may periodically support additional North America Distribution Center initiatives
Responsibilities
  • Serve as the primary IT partner for Memphis Distribution Center operations
  • Define and manage the product roadmap for warehouse management and execution capabilities
  • Partner with business stakeholders to identify opportunities for process improvement, automation, and digital transformation
  • Translate business strategies and operational requirements into product capabilities and technology solutions
  • Prioritize enhancements, technical debt, operational improvements, and project investments based on business value and risk
  • Lead development and delivery of new WMS capabilities, integrations, and enhancements
  • Own and manage product backlogs, epics, user stories, acceptance criteria, and delivery priorities
  • Drive Agile delivery practices while partnering with development, testing, architecture, and support teams
  • Coordinate solution design, testing, deployment, training, cutover, and hypercare activities
  • Support business readiness, user acceptance testing, and change management efforts
  • Maintain accountability for system availability, performance, reliability, and operational support
  • Lead root cause investigations and corrective action plans for production issues
  • Partner with support teams to ensure timely incident resolution and service request fulfillment
  • Monitor key operational metrics and identify opportunities for continuous improvement
  • Ensure warehouse technology solutions support service, quality, compliance, and productivity goals
  • Develop deep understanding of distribution center processes including: Inbound Receiving, Put-Away, Inventory Management, Replenishment, Picking, Packing, Shipping, Transportation Integration, Returns Processing, Cold Chain Operations, Automation and Robotics
  • Identify process optimization opportunities through technology, analytics, automation, and AI-enabled capabilities
  • Support strategic initiatives involving warehouse automation, RF technologies, material handling equipment, and digital supply chain solutions
  • Build strong partnerships with business leaders, site leadership, engineering, and external partners such as 3PL provider
  • Collaborate with product lines, enterprise architecture, infrastructure, cybersecurity, and validation organizations
  • Communicate project status, risks, dependencies, and execution plans to stakeholders and leadership
  • Coordinate activities with software vendors, systems integrators, and third-party logistics providers
  • Ensure compliance with Johnson & Johnson policies, cybersecurity standards, SDLC processes, and regulatory requirements
  • Support validation and documentation activities where required
  • Drive lifecycle management, platform modernization, and risk mitigation initiatives
  • Maintain governance over integration, master data, and system changes affecting warehouse operations
Desired Qualifications
  • Experience with SAP EWM implementations, migrations, or warehouse modernization programs
  • Experience supporting automation, robotics, ASRS, conveyor, or material handling technologies
  • Knowledge of SAP S/4HANA, SAP TM, SAP ERP, or related supply chain applications
  • Experience with cloud technologies, integrations, middleware, or API-driven architecture
  • Exposure to AI, machine learning, analytics, or digital supply chain initiatives
  • Experience supporting FDA, GxP, SOX, or regulated environments
  • Project Management certification and/or Agile certification preferred
  • Strategic thinking and business acumen
  • Technology leadership
  • Product ownership mindset
  • Execution excellence
  • Customer focus
  • Data-driven decision making
  • Continuous improvement orientation
  • Strong collaboration and influencing skills
  • Commitment to Johnson & Johnson Credo values
  • Travel up to 15–25% may be required
  • Hybrid working (3 days in the office and 2 days remote)
  • On-site presence at Memphis Logistics Center is expected
  • This role may periodically support additional North America Distribution Center initiatives
  • Required Skills: Business Process Development, Order to Cash (OTC), Process Flow, Warehouse Management
  • Preferred Skills: Agile Product Development, Analytical Reasoning, Coaching, Collaboration, Competitive Landscape Analysis, Critical Thinking, Customer Alignment, Demand Forecasting, Human-Computer Interaction (HCI), Organizing, Product Development, Product Improvements, Product Strategies, Requirements Analysis, Research and Development, Software Development Life Cycle (SDLC), Software Development Management, Stakeholder Management, Technical Credibility, Technical Writing, Technologically Savvy

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.